{"schema_version":"secwatch.filing_event.v1","accession":"0000910329-25-000015","form_type":"8-K","ticker":"MED","cik":"0000910329","company_name":"MEDIFAST INC","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.665415+00:00","generated_at":"2026-05-17T21:42:49.800689+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Medifast Q2 revenue falls 37.4% to $105.6M; active coaches down 33%; Q3 guidance weak","bullets":["Revenue $105.6M, down 37.4% YoY; active OPTA VIA coaches 22,800 (-32.7% YoY); diluted EPS $0.22 (includes $2.0M net LifeMD gain).","Net income $2.5M vs. loss $8.2M a year ago; operating loss improved to $1.1M from $7.9M.","Cash and investments $162.7M, no debt; LifeMD stake sold during quarter.","Q3 2025 guidance: revenue $70M-$90M; diluted EPS range ($0.60) to $0.00.","Management cites ongoing client acquisition challenges and GLP-1 competition."],"urls":{"canonical":"https://secwatch.observer/filing/0000910329-25-000015","json":"https://secwatch.observer/filing/0000910329-25-000015.json","markdown":"https://secwatch.observer/filing/0000910329-25-000015.md","text":"https://secwatch.observer/filing/0000910329-25-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/910329/000091032925000015/0000910329-25-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910329/000091032925000015/med-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:42:49.800689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}